Levetiracetam Tablet, Film Coated
Product Images NDC 51655-325

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 51655-325). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

51655-325-52 (51655 325 52 Rev A 05 23)

Label for Levetiracetam Tablets, USP 500 mg, film-coated tablets, 30 count, for oral use. The label states the storage conditions (20°-25°C) and cautions to keep out of reach of children and store in the original container. Packaged by Northwind Pharmaceuticals, Indiana, with barcode and NDC 51655-325-52.*

FDA Label Image

Levecamberlogo1 (Levecamberlogo1)

FDA Label Image

Levefig1 (Levefig1)

A bar chart comparing the percentage of patients responding to a placebo and two dosages of Levetiracetam (1000 mg/day and 3000 mg/day). The chart shows the percentages on the vertical axis, highlighting that Levetiracetam groups have higher patient response rates than the placebo group.*

FDA Label Image

Levefig2 (Levefig2)

A bar chart showing the percentage of patients for placebo and two Levetiracetam dose groups: 1000 mg/day and 2000 mg/day. The chart displays higher patient percentages in the Levetiracetam groups compared to placebo, with values approximately 6.3% for placebo, 20.8% for 1000 mg/day, and 35.2% for 2000 mg/day.*

FDA Label Image

Levefig3 (Levefig3)

A bar chart comparing the percentage of patients between two groups: Placebo (N=104) with 14.4%, and Levetiracetam 3000 mg/day (N=180) with 39.4%. The y-axis represents the percentage of patients, and the x-axis shows the two treatment groups.*

FDA Label Image

Levefig4 (Levefig4)

A bar graph comparing the percentage of patients between placebo and Levetiracetam groups. The x-axis represents treatment groups (Placebo and Levetiracetam), while the y-axis shows the percentage of patients, with Levetiracetam group having a visibly higher percentage (44.6%) than the placebo group (19.6%).*

FDA Label Image

Levefig5 (Levefig5)

A bar chart comparing the percentage of subjects with an unspecified outcome between a placebo group (45.2%) and a Levetiracetam treatment group (72.2%). The chart includes numerical values atop each bar indicating the respective percentages.*

FDA Label Image

Levefig6 (Levefig6)

A bar chart comparing the percent efficacy of Levetiracetam 500 mg film-coated tablets versus placebo. The graph shows Levetiracetam with approximately 72.2% efficacy and placebo with 45.2%, with sample sizes noted for each group.*

FDA Label Image

Levestructure (Levestructure)

Chemical structure of levetiracetam, showing its molecular framework including a pyrrolidone ring attached to an ethyl side chain and an amide group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.